Enzo Biochem, Inc.: $100m revs in F18. Pioneer in molecular diagnostics (Dx), leading convergence of clinical laboratories, life sciences and IP through devt of unique Dx platform technologies providing numerous advantages over previous standards.
Healthcare/Medical Diagnostics & Research
Based in...
US - Middle Atlantic
Clinical Stage
Disease Space
Biotechnology, Diagnostics
Public, USA
Market Cap
100MM - 500MM
527 Madison Avenue
New York, NY NY 10022
United States

Top 10 Holders of Enzo Biochem, Inc.

Institution OS (%) Position Mkt Val ($MM) Source Filing Date
Harbert Fund Advisors, Inc. 11.82 5,620,681 12.98 13F 6/30/20
Renaissance Technologies LLC 7.29 3,465,278 8.00 13F 6/30/20
Evermore Global Advisors LLC 6.76 3,216,704 7.43 13F 6/30/20
The Vanguard Group, Inc. 5.01 2,383,027 5.50 Funds 8/31/20
Vanguard Group, Inc. (Subfiler) 4.93 2,343,716 5.41 13F 6/30/20
Dimensional Fund Advisors LP 4.13 1,962,709 4.53 13F 6/30/20
BlackRock Institutional Trust Co. NA 3.66 1,741,689 4.02 13F 6/30/20
BlackRock Fund Advisors 3.01 1,431,082 3.31 13F 6/30/20
Wellington Management Co. LLP 2.25 1,069,890 2.47 13F 6/30/20
State Street Corp. 1.69 806,072 1.86 13F 6/30/20
Ownership data is sourced through FactSet.

Stock Market Data

Data is being loaded...
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2020 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, RTB=Real-Time BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.